1.
Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for
Study
1.2.3. Key Market
Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the
Market
3.2. Overview of Key
Market Segmentations
3.3. Overview of Key
Market Players
3.4. Overview of Key
Regions/Countries
3.5. Overview of Market
Drivers, Challenges, Trends
4.
Voice of Customer
4.1.
Adalimumab Demand, By Therapeutic Area
4.2.
Adalimumab Demand, By Region
4.3.
Adalimumab Demand, By Gender
4.4.
Adalimumab Demand, By Patient Population
4.5.
Commonly Observed Side-Effects
4.6.
Brand Awareness
5.
Pharmacodynamic Overview of Adalimumab
5.1.
Mechanism of Action
5.2.
Absorption
5.3.
Volume of Distribution
5.4.
Route of Elimination
5.5.
Half Life
5.6.
Clearance
5.7.
Toxicity
6.
Clinical Trials
6.1.
Ongoing Clinical Trials
6.2.
Completed Clinical Trials
6.3.
Terminated Clinical Trials
6.4.
Clinical Trial Analysis
7.
Patent Analysis
7.1.
Patent Granted
7.2.
Patent Applications Filed
8. Global Adalimumab
Market Outlook
8.1.
Market Size & Forecast
8.1.1.
By Value
8.2.
Market Share & Forecast
8.2.1.
By Type (Biologics v/s Biosimilars)
8.2.2.
By Product Type (Branded v/s Generics)
8.2.3.
By Therapeutic Area (Rheumatoid Arthritis, Psoriatic
Arthritis, Psoriasis, Crohn’s Disease, Others)
8.2.4.
Distribution Channel (Hospital Pharmacies, Retail
Pharmacies, Online Pharmacies, Others)
8.2.5.
By End User (Hospitals & Clinics, Home Healthcare,
Others)
8.2.6.
By Company (2022)
8.2.7. By
Region
8.3.
Product Market Map
9. North America
Adalimumab Market Outlook
9.1.
Market Size & Forecast
9.1.1.
By Value & Volume
9.2.
Market Share & Forecast
9.2.1.
By Type
9.2.2.
By Product Type
9.2.3.
By Therapeutic Area
9.2.4.
By Distribution Channel
9.2.5.
By End User
9.2.6.
By Country
9.3.
North America: Country Analysis
9.3.1.
United States Adalimumab Market Outlook
9.3.1.1.
Market Size & Forecast
9.3.1.1.1.
By Value
9.3.1.2.
Market Share & Forecast
9.3.1.2.1.
By Type
9.3.1.2.2.
By Product Type
9.3.1.2.3.
By Therapeutic Area
9.3.1.2.4.
By Distribution Channel
9.3.1.2.5.
By End User
9.3.2.
Mexico Adalimumab Market Outlook
9.3.2.1.
Market Size & Forecast
9.3.2.1.1.
By Value
9.3.2.2.
Market Share & Forecast
9.3.2.2.1.
By Type
9.3.2.2.2.
By Product Type
9.3.2.2.3.
By Therapeutic Area
9.3.2.2.4.
By Distribution Channel
9.3.2.2.5.
By End User
9.3.3.
Canada Adalimumab Market Outlook
9.3.3.1.
Market Size & Forecast
9.3.3.1.1.
By Value
9.3.3.2.
Market Share & Forecast
9.3.3.2.1.
By Type
9.3.3.2.2.
By Product Type
9.3.3.2.3.
By Therapeutic Area
9.3.3.2.4.
By Distribution Channel
9.3.3.2.5.
By End User
10. Europe Adalimumab
Market Outlook
10.1.
Market Size & Forecast
10.1.1.
By Value & Volume
10.2.
Market Share & Forecast
10.2.1.
By Type
10.2.2.
By Product Type
10.2.3.
By Therapeutic Area
10.2.4.
By Distribution Channel
10.2.5.
By End User
10.2.6.
By Country
10.3.
Europe: Country Analysis
10.3.1.
France Adalimumab Market Outlook
10.3.1.1.
Market Size & Forecast
10.3.1.1.1.
By Value
10.3.1.2.
Market Share & Forecast
10.3.1.2.1.
By Type
10.3.1.2.2.
By Product Type
10.3.1.2.3.
By Therapeutic Area
10.3.1.2.4.
By Distribution Channel
10.3.1.2.5.
By End User
10.3.2.
Germany Adalimumab Market Outlook
10.3.2.1.
Market Size & Forecast
10.3.2.1.1.
By Value
10.3.2.2.
Market Share & Forecast
10.3.2.2.1.
By Type
10.3.2.2.2.
By Product Type
10.3.2.2.3.
By Therapeutic Area
10.3.2.2.4.
By Distribution Channel
10.3.2.2.5.
By End User
10.3.3.
United Kingdom Adalimumab Market Outlook
10.3.3.1.
Market Size & Forecast
10.3.3.1.1.
By Value
10.3.3.2.
Market Share & Forecast
10.3.3.2.1.
By Type
10.3.3.2.2.
By Product Type
10.3.3.2.3.
By Therapeutic Area
10.3.3.2.4.
By Distribution Channel
10.3.3.2.5.
By End User
10.3.4.
Italy Adalimumab Market Outlook
10.3.4.1.
Market Size & Forecast
10.3.4.1.1.
By Value
10.3.4.2.
Market Share & Forecast
10.3.4.2.1.
By Type
10.3.4.2.2.
By Product Type
10.3.4.2.3.
By Therapeutic Area
10.3.4.2.4.
By Distribution Channel
10.3.4.2.5.
By End User
10.3.5.
Spain Adalimumab Market Outlook
10.3.5.1.
Market Size & Forecast
10.3.5.1.1.
By Value
10.3.5.2.
Market Share & Forecast
10.3.5.2.1.
By Type
10.3.5.2.2.
By Product Type
10.3.5.2.3.
By Therapeutic Area
10.3.5.2.4.
By Distribution Channel
10.3.5.2.5.
By End User
11. Asia-Pacific
Adalimumab Market Outlook
11.1.
Market Size & Forecast
11.1.1.
By Value & Volume
11.2.
Market Share & Forecast
11.2.1.
By Type
11.2.2.
By Product Type
11.2.3.
By Therapeutic Area
11.2.4.
By Distribution Channel
11.2.5.
By End User
11.2.6.
By Country
11.3.
Asia-Pacific: Country Analysis
11.3.1.
China Adalimumab Market Outlook
11.3.1.1.
Market Size & Forecast
11.3.1.1.1.
By Value
11.3.1.2.
Market Share & Forecast
11.3.1.2.1.
By Type
11.3.1.2.2.
By Product Type
11.3.1.2.3.
By Therapeutic Area
11.3.1.2.4.
By Distribution Channel
11.3.1.2.5.
By End User
11.3.2.
India Adalimumab Market Outlook
11.3.2.1.
Market Size & Forecast
11.3.2.1.1.
By Value
11.3.2.2.
Market Share & Forecast
11.3.2.2.1.
By Type
11.3.2.2.2.
By Product Type
11.3.2.2.3.
By Therapeutic Area
11.3.2.2.4.
By Distribution Channel
11.3.2.2.5.
By End User
11.3.3.
South Korea Adalimumab Market Outlook
11.3.3.1.
Market Size & Forecast
11.3.3.1.1.
By Value
11.3.3.2.
Market Share & Forecast
11.3.3.2.1.
By Transgenic Crop
11.3.3.2.2.
By Technique
11.3.3.2.3.
By Application
11.3.3.2.4.
By End User
11.3.4.
Japan Adalimumab Market Outlook
11.3.4.1.
Market Size & Forecast
11.3.4.1.1.
By Value
11.3.4.2.
Market Share & Forecast
11.3.4.2.1.
By Type
11.3.4.2.2.
By Product Type
11.3.4.2.3.
By Therapeutic Area
11.3.4.2.4.
By Distribution Channel
11.3.4.2.5.
By End User
11.3.5.
Australia Adalimumab Market Outlook
11.3.5.1.
Market Size & Forecast
11.3.5.1.1.
By Value
11.3.5.2.
Market Share & Forecast
11.3.5.2.1.
By Type
11.3.5.2.2.
By Product Type
11.3.5.2.3.
By Therapeutic Area
11.3.5.2.4.
By Distribution Channel
11.3.5.2.5.
By End User
12. South America
Adalimumab Market Outlook
12.1.
Market Size & Forecast
12.1.1.
By Value & Volume
12.2.
Market Share & Forecast
12.2.1.
By Type
12.2.2.
By Product Type
12.2.3.
By Therapeutic Area
12.2.4.
By Distribution Channel
12.2.5.
By End User
12.2.6.
By Country
12.3.
South America: Country Analysis
12.3.1.
Brazil Adalimumab Market Outlook
12.3.1.1.
Market Size & Forecast
12.3.1.1.1.
By Value
12.3.1.2.
Market Share & Forecast
12.3.1.2.1.
By Type
12.3.1.2.2.
By Product Type
12.3.1.2.3.
By Therapeutic Area
12.3.1.2.4.
By Distribution Channel
12.3.1.2.5.
By End User
12.3.2.
Argentina Adalimumab Market Outlook
12.3.2.1.
Market Size & Forecast
12.3.2.1.1.
By Value
12.3.2.2.
Market Share & Forecast
12.3.2.2.1.
By Type
12.3.2.2.2.
By Product Type
12.3.2.2.3.
By Therapeutic Area
12.3.2.2.4.
By Distribution Channel
12.3.2.2.5.
By End User
12.3.3.
Colombia Adalimumab Market Outlook
12.3.3.1.
Market Size & Forecast
12.3.3.1.1.
By Value
12.3.3.2.
Market Share & Forecast
12.3.3.2.1.
By Type
12.3.3.2.2.
By Product Type
12.3.3.2.3.
By Therapeutic Area
12.3.3.2.4.
By Distribution Channel
12.3.3.2.5.
By End User
13. Middle East and
Africa Adalimumab Market Outlook
13.1.
Market Size & Forecast
13.1.1.
By Value & Volume
13.2.
Market Share & Forecast
13.2.1.
By Type
13.2.2.
By Product Type
13.2.3.
By Therapeutic Area
13.2.4.
By Distribution Channel
13.2.5.
By End User
13.2.6.
By Country
13.3.
MEA: Country Analysis
13.3.1.
South Africa Adalimumab Market Outlook
13.3.1.1.
Market Size & Forecast
13.3.1.1.1.
By Value
13.3.1.2.
Market Share & Forecast
13.3.1.2.1.
By Type
13.3.1.2.2.
By Product Type
13.3.1.2.3.
By Therapeutic Area
13.3.1.2.4.
By Distribution Channel
13.3.1.2.5.
By End User
13.3.2.
Saudi Arabia Adalimumab Market Outlook
13.3.2.1.
Market Size & Forecast
13.3.2.1.1.
By Value
13.3.2.2.
Market Share & Forecast
13.3.2.2.1.
By Type
13.3.2.2.2.
By Product Type
13.3.2.2.3.
By Therapeutic Area
13.3.2.2.4.
By Distribution Channel
13.3.2.2.5.
By End User
13.3.3.
UAE Adalimumab Market Outlook
13.3.3.1.
Market Size & Forecast
13.3.3.1.1.
By Value
13.3.3.2.
Market Share & Forecast
13.3.3.2.1.
By Type
13.3.3.2.2.
By Product Type
13.3.3.2.3.
By Therapeutic Area
13.3.3.2.4.
By Distribution Channel
13.3.3.2.5.
By End User
14.
Market Dynamics
14.1.
Drivers
14.2.
Challenges
15.
Market Trends & Developments
16.
Competitive Landscape
16.1.
Abbvie Inc.
16.2.
Pfizer, Inc.
16.3.
Amgen Inc.
16.4.
Novartis AG
16.5.
Torrent
Pharmaceuticals Ltd.
16.6.
Cadila Healthcare
Limited
16.7.
Boehringer Ingelheim
International GmbH
16.8.
Mylan N.V.
16.9.
Hetero Biopharma Ltd
16.10.
Samsung Bioepis Co
Ltd.
17. Strategic Recommendations
18. About Us & Disclaimer